Agency IQ

JANUARY 26, 2024

The cost of artificially short expiration dates: Worsened shortages, higher costs and more waste As drug shortages have made headlines over the past few years, the FDA has announced the extension of expiration dates on a variety of drug products. The results of this survey were provided in a report to the AMA’s Council on Scientific Affairs.

Science 40

Science FDA Packaging Production 40

Agency IQ

DECEMBER 1, 2023

What We Expect the FDA to do in December 2023 In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the month ahead, including key deadlines, meetings, events, planned regulations, comment periods and more. This is what OIRA is currently reviewing.

FDA 40

FDA Science Regulations Production 40

Agency IQ

OCTOBER 27, 2023

What We Expect the FDA to do in November 2023 In this ongoing feature, AgencyIQ looks at public data to determine what the FDA is likely to do in the month ahead, including key deadlines, meetings, events, planned regulations, comment periods and more. Government shutdown: At present, the U.S.

FDA 40

FDA Science Regulations Production 40

The Pharma Data

AUGUST 6, 2020

See “Worldwide Pro Forma Revenue” in Quarterly Package of Financial Information for this quarter, which is available on bms.com/investors/financial-reporting/quarterly-results, for information on the revenue of the company and Celgene on a stand-alone basis for the prior-year period. Oncology and Hematology. Regulatory. Regulatory.

Production 52

Production International Licensing Licensing 52

The Pharma Data

JUNE 18, 2021

IMBRUVICA is the only FDA-approved medicine in WM and cGVHD. IMBRUVICA was one of the first medicines to receive FDA approval via the Breakthrough Therapy Designation pathway. 9 VENCLEXTA (venetoclax) [Package Insert].?North BTK signaling is needed by specific cancer cells to multiply and spread. 8 IMBRUVICA U.S.

Treatment 40

Treatment FDA FDA Approval Therapies 40

Agency IQ

MARCH 7, 2024

BY LAURA DIANGELO, MPH | MAR 6, 2024 5:54 PM CST Fiscal year 2024 appropriations bills On March 3, 2024, House and Senate appropriators released a package of final fiscal year (FY) 2024 appropriations bills. The new bill is intended to serve as the FY2024 appropriations, and stave off a shutdown of government operations.

FDA 40

FDA Packaging Science Drugs 40

The Pharma Data

JUNE 18, 2021

IMBRUVICA is the only FDA-approved medicine in WM and cGVHD. IMBRUVICA was one of the first medicines to receive FDA approval via the Breakthrough Therapy Designation pathway. 8 VENCLEXTA (venetoclax) [Package Insert].?North?Chicago, BTK signaling is needed by specific cancer cells to multiply and spread.

Treatment 52

Treatment Therapies FDA FDA Approval 52

The Pharma Data

MAY 5, 2021

FDA approves 100th monoclonal antibody product ( Nature Reviews Drug Discovery ). AI, digital health feature in latest batch of FDA breakthrough device designations ( MedTech Dive ). BD Taps Contract Packager for COVID-19 Test Kits ( MD+DI ). Government & Regulatory.

Vaccine 52

Vaccine FDA FDA Approval International 52

Drug & Device Law

DECEMBER 29, 2023

2023) (federal government may unilaterally obtain dismissal of FCA claims, and calling the constitutionality of the FCA’s private enforcement mechanism into question) ( here ); Quishenberry v. The case was governed by North Carolina substantive law, and NC rejects strict liability altogether. Polansky v. UnitedHealthcare, Inc. ,

Testimonials 105

Testimonials FDA Drugs Vaccine 105